Gsa Capital Partners LLP Scynexis Inc Transaction History
Gsa Capital Partners LLP
- $1.2 Billion
- Q3 2025
A detailed history of Gsa Capital Partners LLP transactions in Scynexis Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 104,423 shares of SCYX stock, worth $61,609. This represents 0.01% of its overall portfolio holdings.
Number of Shares
104,423
Previous 53,507
95.16%
Holding current value
$61,609
Previous $36,000
122.22%
% of portfolio
0.01%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding SCYX
# of Institutions
46Shares Held
12.5MCall Options Held
0Put Options Held
0-
Avidity Partners Management LP Dallas, TX3.35MShares$1.98 Million1.43% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY2.24MShares$1.32 Million0.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.76MShares$1.04 Million0.0% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA1.58MShares$934,1750.0% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC556KShares$327,7770.7% of portfolio
About SCYNEXIS INC
- Ticker SCYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 32,651,800
- Market Cap $19.3M
- Description
- SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...